文献速递支持与姑息治疗

冷冻手套预防化疗所致周围神经病变的多中心随机对照试验

Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy.
PubMed 文献 · Ann Oncol · 2020-01-01

多中心随机对照试验纳入180例接受奥沙利铂、多西他赛或紫杉醇化疗的癌症患者,随机分为冷冻手套组和对照组。意向性分析显示两组EORTC QLQ CIPN20亚量表无重要差异,但冷冻手套组手指/手部刺痛及因手部力量下降开瓶困难减轻,总体生活质量和躯体功能更好;34%患者因不适停用冷冻手套。

要点

  • 冷冻手套未显著改善CIPN20总体亚量表评分,但可能减轻手部部分神经病变症状。
  • 冷冻手套组总体生活质量和躯体功能优于对照组。
  • 约三分之一患者因不适中断冷冻手套,需关注耐受性。

核心结论

  • 两组CIPN亚量表无差异,但佩戴冷冻手套可能减轻部分手部神经病变症状并改善生活质量。

研究设计与样本

  • 多中心随机对照试验,2013年2月至2016年5月纳入180例开始奥沙利铂、多西他赛或紫杉醇治疗的癌症患者,冷冻手套组与对照组各90例。

主要发现

  • 意向性分析显示冷冻手套组手指/手部刺痛减轻(β=-10.20,95%CI -3.94至-3.14,P=0.005),因手部力量下降开瓶困难减少(β=-6.97,95%CI -13.53至-0.40,P=0.04)。
  • 符合方案分析显示冷冻手套组手指/手部酸痛或烧灼痛减轻(β=-4.37,95%CI -7.90至-0.83,P=0.02),手部痉挛减少(β=-3.76,95%CI -7.38至-0.14,P=0.04)。
  • 冷冻手套组总体生活质量(β=4.79,95%CI 0.37至9.22,P=0.03)和躯体功能(β=5.66,95%CI 1.59至9.73,P=0.007)优于对照组。

临床怎么用

  • 冷冻手套可考虑用于接受奥沙利铂、多西他赛或紫杉醇化疗患者以减轻手部部分神经病变症状,但需评估耐受性。

局限性

  • 约三分之一冷冻手套组患者治疗结束前停药,可能影响依从性和结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study investigated the efficacy and tolerability of wearing frozen gloves (FGs) during chemotherapy to prevent chemotherapy-induced peripheral neuropathy (CIPN) as reported by patients and influence on quality of life (QoL). PATIENTS AND METHODS: Cancer patients starting treatment with oxaliplatin, docetaxel or paclitaxel between February 2013 and May 2016 at the medical oncology department were eligible. Patients were randomized into groups wearing FGs on both hands during treatment and those not wearing FGs during treatment. Self-reported CIPN and QoL were measured with the European Organisation for the Research and Treatment of Cancer Quality of Life (EORTC QLQ) CIPN20 and QLQ-C30 at four time points: baseline (t0), after three cycles (t1), end of chemotherapy (t2) and after 6 months (t3). RESULTS: The study included 180 patients with 90 patients in both arms. They mostly underwent treatment of colorectal or breast cancer. Thirty-one patients (34%) discontinued FGs, mainly due to discomfort. Intention-to-treat analyses showed no important differences in reported EORTC QLQ CIPN20 subscales between the FG group and control group; however, the analyses showed the patients experienced reduced tingling in fingers/hands [β = -10.20, 95% confidence interval (CI) = -3.94 to -3.14, P = 0.005] and less trouble opening a jar or bottle due to loss of strength in hands (β = -6.97, 95% CI = -13.53 to -0.40, P = 0.04) in the FG group compared with the control group. Per-protocol analyses showed similar results: reduced aching or burning pain in fingers/hands (β = -4.37, 95% CI = -7.90 to -0.83, P = 0.02) and cramps in hands (β = -3.76, 95% CI = -7.38 to -0.14, P = 0.04). Differences in tingling in fingers/hands at t1 were clinically relevant. In addition, those treated with FGs reported overall better QoL (β = 4.79, 95% CI = 0.37 to 9.22, P = 0.03) and physical functioning (β = 5.66, 95% CI = 1.59 to 9.73, P = 0.007) than the control. No difference in dose reductions was observed. CONCLUSIONS: No difference in CIPN subscales was reported between intervention arms. Wearing FGs might reduce some neuropathy symptoms in the hands, potentially resulting in a better QoL; however, one-third of the FG group discontinued the study before the end of treatment. Future studies should focus on the method of limb hypothermia to prevent CIPN. TRIAL REGISTRATION NUMBER: NL39650.015.12.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Beijers AJM, Bonhof CS, Mols F, et al. Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy. Ann Oncol. 2020. PMID: 31912787. doi:10.1016/j.annonc.2019.09.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。